This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Piper Jaffray (NYSE: PJC) is pleased to announce the addition of Dr. Charles Duncan as managing director and senior research analyst in its biotechnology research platform. He will be based in the firm’s New York office, focused specifically on small- and mid-cap emerging growth biotechnology companies.
Duncan brings more than 17 years of sell-side experience, most recently serving as an analyst at JMP Securities since 2002, and previously at Dresdner Kleinwort Wasserstein, Vector Healthcare Group - Prudential Securities, Tucker Anthony Cleary Gull and Chatfield Dean & Co. Duncan has been recognized by industry sources, including the StarMine Analyst Awards, as being among the best analysts for his fundamental and timely analysis.